Edgewise Therapeutics Inc (NASDAQ:EWTX) shares, rose in value on Wednesday, April 16, with the stock price up by 0.08% to the previous day’s close as strong demand from buyers drove the stock to $13.03.
Actively observing the price movement in the last trading, the stock closed the session at $13.02, falling within a range of $12.5001 and $13.27. The value of beta (5-year monthly) was 0.328. Referring to stock’s 52-week performance, its high was $38.12, and the low was $10.60. On the whole, EWTX has fluctuated by -50.89% over the past month.
With the market capitalization of Edgewise Therapeutics Inc currently standing at about $1.37 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-02.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that EWTX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of EWTX currently trading nearly -23.91% and -42.55% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 29.68, while the 7-day volatility ratio is showing 8.44% which for the 30-day chart, stands at 11.79%. Furthermore, Edgewise Therapeutics Inc (EWTX)’s beta value is 0.50, and its average true range (ATR) is 1.91.
A comparison of Edgewise Therapeutics Inc (EWTX) with its peers suggests the former has fared considerably weaker in the market. EWTX showed an intraday change of 0.08% in last session, and over the past year, it shrunk by -20.93%%.
Data on historical trading for Edgewise Therapeutics Inc (NASDAQ:EWTX) indicates that the trading volumes over the past 10 days have averaged 3.14 and over the past 3 months, they’ve averaged 1.75 million. According to company’s latest data on outstanding shares, there are 94.84 million shares outstanding.
Nearly 29.63% of Edgewise Therapeutics Inc’s shares belong to company insiders and institutional investors own 71.35% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 10.39 million shares as on 2025-03-31, resulting in a short ratio of 6.8. According to the data, the short interest in Edgewise Therapeutics Inc (EWTX) stood at 1591.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 8.73 million. The stock has fallen by -51.20% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the EWTX stock heading into the next quarter.
